As of 2026-04-15, the EV/EBITDA ratio of Sangamo Therapeutics Inc (SGMO) is -0.65. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGMO's latest enterprise value is 70.42 mil USD. SGMO's TTM EBITDA according to its financial statements is -107.61 mil USD. Dividing these 2 quantities gives us the above SGMO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 18.9x | 16.2x |
| Forward P/E multiples | 19.1x - 25.2x | 21.0x |
| Fair Price | (5.71) - (5.63) | (5.54) |
| Upside | -2331.1% - -2302.9% | -2267.5% |
| Date | EV/EBITDA |
| 2026-04-13 | -0.67 |
| 2026-04-10 | -0.64 |
| 2026-04-09 | -0.67 |
| 2026-04-08 | -0.65 |
| 2026-04-07 | -0.66 |
| 2026-04-06 | -0.73 |
| 2026-04-02 | -0.80 |
| 2026-04-01 | -0.67 |
| 2026-03-31 | -0.62 |
| 2026-03-30 | -0.83 |
| 2026-03-27 | -0.87 |
| 2026-03-26 | -0.95 |
| 2026-03-25 | -0.97 |
| 2026-03-24 | -0.97 |
| 2026-03-23 | -0.92 |
| 2026-03-20 | -0.91 |
| 2026-03-19 | -0.94 |
| 2026-03-18 | -1.00 |
| 2026-03-17 | -1.07 |
| 2026-03-16 | -1.00 |
| 2026-03-13 | -1.06 |
| 2026-03-12 | -1.12 |
| 2026-03-11 | -1.16 |
| 2026-03-10 | -1.18 |
| 2026-03-09 | -1.17 |
| 2026-03-06 | -1.06 |
| 2026-03-05 | -1.06 |
| 2026-03-04 | -1.12 |
| 2026-03-03 | -1.11 |
| 2026-03-02 | -1.23 |
| 2026-02-27 | -1.24 |
| 2026-02-26 | -1.27 |
| 2026-02-25 | -1.37 |
| 2026-02-24 | -1.37 |
| 2026-02-23 | -1.11 |
| 2026-02-20 | -1.08 |
| 2026-02-19 | -1.07 |
| 2026-02-18 | -1.01 |
| 2026-02-17 | -1.03 |
| 2026-02-13 | -1.09 |
| 2026-02-12 | -1.06 |
| 2026-02-11 | -1.10 |
| 2026-02-10 | -1.10 |
| 2026-02-09 | -1.13 |
| 2026-02-06 | -1.13 |
| 2026-02-05 | -0.98 |
| 2026-02-04 | -1.00 |
| 2026-02-03 | -1.10 |
| 2026-02-02 | -1.69 |
| 2026-01-30 | -1.58 |